Clinical Trial Update: A Phase I/II Study of Intratumoral Injection of SD-101 [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial investigating intratumoral SD-101 for various B-cell lymphomas; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
• Follicular Lymphoma
• Marginal Zone Lymphoma
• Nodal Marginal Zone B-cell Lymphoma
• Small Lymphocytic Lymphoma
• Splenic Marginal Zone Lymphoma

Drugs mentioned

• SD-101

Snippet

Sponsor: Robert Lowsky | Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-09-29